| --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | © Aeglea BioTherapeutics \| EXTERNAL SEPTEMBER 2019 Aeglea Corporate Overview | | | | --- ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 AEGLEA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorpor ...

| --- | --- | --- | --- | --- | --- | |-------|--------|--------------------------------------------------|--------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Aeglea | © Aeglea BioTherapeutics \| EXTERNAL JUNE 2019 | Corporate Overview \| 06.05.19 | | | | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 AEGLEA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorpo ...

© Aeglea BioTherapeutics APRIL 2019 | --- | --- ...

Aeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants David Calusdian - IR, Sharon Merrill Associates Anthony Quinn - Chief Executive Officer Charles York - Chief Financial Officer Jim Wooldridge - Chief Medical Officer Conference Call Participants Josh Schimmer - Evercore ISI Rajvindra Gill - Needham and Company Matthew Cross - H.C. Wainwright Operator Greetings and welcome to the Fourth Quarter 2018 Corporate Update and Earnings Call. And at this time ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37722 AEGLEA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-4312787 (State or Other Jurisdiction of Incorpo ...